Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination

References

• Centers for Disease Control and Prevention. Progress in introduction of pneumococcal conjugate vaccine – worldwide, 2000–2008. MMWR Morb. Mortal. Wkly Rep.57(42), 1148–1151 (2008).
   PubMedGoogle Scholar
• De Carvalho GH, Muscat M, Monnet DL, Giesecke J, Lopalco PL. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001–2007. Euro. Surveill.14(12), pii: 19159 (2009).
   Google Scholar
• Rozenbaum MH, Sanders EA, van Hoek AJ et al. Cost–effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. Br. Med. J.340, c2509 (2010).
   PubMed Web of Science ®Google Scholar
• Hsu HE, Shutt KA, Moore MR et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N. Engl. J. Med.360(3), 244–256 (2009).
   PubMed Web of Science ®Google Scholar
• Lexau CA, Lynfield R, Danila R et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA294(16), 2043–2051 (2005).
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N. Engl. J. Med.348(18), 1737–1746 (2003).
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, Hoek AJ, Hak E, Postma MJ. Huge impact of assumptions on indirect effects on the cost–effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). Vaccine28(12), 2367–2369 (2010).
   PubMed Web of Science ®Google Scholar
• Changing epidemiology of pneumococcal serotypes after introduction of conjugate vaccine: July 2010 report. Wkly Epidemiol. Rec.85(43), 434–436 (2010).
   PubMedGoogle Scholar
• Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect. Dis.5(2), 83–93 (2005).
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin. Infect. Dis.30(1), 100–121 (2000).
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J.19(3), 187–195 (2000).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Ashton L et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J.25(4), 312–319 (2006).
   PubMed Web of Science ®Google Scholar
• Whitney CG, Pilishvili T, Farley MM et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case–control study. Lancet368(9546), 1495–1502 (2006).
   PubMed Web of Science ®Google Scholar
• Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev. Vaccines8(11), 1479–1500 (2009).
   PubMed Web of Science ®Google Scholar
• Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics125(5), 866–875 (2010).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr. Infect. Dis. J.28(4 Suppl.), S66–S76 (2009).
   PubMed Web of Science ®Google Scholar
• Kayhty H, Ahman H, Eriksson K, Sorberg M, Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr. Infect. Dis. J.24(2), 108–114 (2005).
   PubMed Web of Science ®Google Scholar
• van Gils EJ, Veenhoven RH, Hak E et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA302(2), 159–167 (2009).
   PubMed Web of Science ®Google Scholar
• Ghaffar F, Barton T, Lozano J et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin. Infect. Dis.39(7), 930–938 (2004).
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Millar EV, Zell ER et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J. Infect. Dis.196(8), 1211–1220 (2007).
   PubMed Web of Science ®Google Scholar
• Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I, Klugman KP. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis.180(4), 1171–1176 (1999).
   PubMed Web of Science ®Google Scholar
• Pelton SI, Loughlin AM, Marchant CD. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr. Infect. Dis. J.23(11), 1015–1022 (2004).
   PubMed Web of Science ®Google Scholar
• Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med.344(6), 403–409 (2001).
   PubMed Web of Science ®Google Scholar
• Robinson KA, Baughman W, Rothrock G et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA285(13), 1729–1735 (2001).
   PubMed Web of Science ®Google Scholar
• Jefferson T, Ferroni E, Curtale F, Giorgi RP, Borgia P. Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old. Lancet Infect. Dis.6(7), 405–410 (2006).
   PubMed Web of Science ®Google Scholar
• Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.49(RR-9), 1–35 (2000).
   PubMedGoogle Scholar
• Singleton RJ, Hennessy TW, Bulkow LR et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA297(16), 1784–1792 (2007).
   PubMed Web of Science ®Google Scholar
• Weatherholtz R, Millar EV, Moulton LH et al. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin. Infect. Dis.50(9), 1238–1246 (2010).
   PubMed Web of Science ®Google Scholar
• Lacapa R, Bliss SJ, Larzelere-Hinton F et al. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin. Infect. Dis.47(4), 476–484 (2008).
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis.201(1), 32–41 (2010).
   PubMed Web of Science ®Google Scholar
• Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction – eight states, 1998–2005. MMWR Morb. Mortal. Wkly Rep.57(6), 144–148 (2008).
   PubMedGoogle Scholar
• Byington CL, Hulten KG, Ampofo K et al. Molecular epidemiology of pediatric pneumococcal empyema 2001–2007. J. Clin. Microbiol.48(2), 520–525 (2010).
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Barson WJ, Lin PL et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics125(3), 429–436 (2010).
   PubMed Web of Science ®Google Scholar
• Moore MR, Gertz RE Jr, Woodbury RL et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis.197(7), 1016–1027 (2008).
   PubMed Web of Science ®Google Scholar
• Flannery B, Heffernan RT, Harrison LH et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann. Intern. Med.144(1), 1–9 (2006).
   PubMed Web of Science ®Google Scholar
• Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998–2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin. Infect. Dis.49(2), 205–212 (2009).
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Scheifele DW, Kellner JD et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, immunization monitoring program, active 2000–2007. Vaccine28(9), 2130–2136 (2010).
   PubMed Web of Science ®Google Scholar
• Roche PW, Krause VL, Bartlett M et al. Invasive pneumococcal disease in Australia, 2004. Commun. Dis. Intell.30(1), 80–92 (2006).
   Google Scholar
• Roche PW, Krause V, Cook H et al. Invasive pneumococcal disease in Australia, 2006. Commun. Dis. Intell.32(1), 18–30 (2008).
   PubMedGoogle Scholar
• Lepoutre A, Varon E, Georges S, Gutmann L, Levy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001–2006. Euro. Surveill.13(35), pii: 18962 (2008).
   PubMedGoogle Scholar
• Bingen E, Levy C, Varon E et al. Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation. Eur. J. Clin. Microbiol. Infect. Dis.27(3), 191–199 (2008).
   PubMed Web of Science ®Google Scholar
• Dubos F, Marechal I, Husson MO, Courouble C, Aurel M, Martinot A. Decline in pneumococcal meningitis after the introduction of the heptavalent-pneumococcal conjugate vaccine in northern France. Arch. Dis. Child92(11), 1009–1012 (2007).
   PubMed Web of Science ®Google Scholar
• Ardanuy C, Tubau F, Pallares R et al. Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997–2007. Clin. Infect. Dis.48(1), 57–64 (2009).
   PubMed Web of Science ®Google Scholar
• Calbo E, Diaz A, Canadell E et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin. Microbiol. Infect.12(9), 867–872 (2006).
   PubMed Web of Science ®Google Scholar
• Obando I, Arroyo LA, Sanchez-Tatay D et al. Molecular epidemiology of paediatric invasive pneumococcal disease in southern Spain after the introduction of heptavalent pneumococcal conjugate vaccine. Clin. Microbiol. Infect.13(3), 347–348 (2007).
   PubMed Web of Science ®Google Scholar
• Guevara M, Barricarte A, Gil-Setas A et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin. Microbiol. Infect.15(11), 1013–1019 (2009).
   PubMed Web of Science ®Google Scholar
• Perez-Trallero E, Marimon JM, Ercibengoa M, Vicente D, Perez-Yarza EG. Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Eur. J. Clin. Microbiol. Infect. Dis.28(7), 731–738 (2009).
   PubMed Web of Science ®Google Scholar
• Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin. Infect. Dis.46(2), 174–182 (2008).
   PubMed Web of Science ®Google Scholar
• Aristegui J, Bernaola E, Pocheville I et al. Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur. J. Clin. Microbiol. Infect. Dis.26(5), 303–310 (2007).
   PubMed Web of Science ®Google Scholar
• Casado-Flores J, Rodrigo C, Aristegui J, Martinon JM, Fenoll A, Mendez C. Decline in pneumococcal meningitis in Spain after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J.27(11), 1020–1022 (2008).
   PubMed Web of Science ®Google Scholar
• Benito-Fernández J, Raso SM, Pocheville-Gurutzeta I, SánchezEtxaniz J, Azcunaga-Santibañez B, Capapé-Zache S. Pneumococcal bacteremia among infants with fever without known source before and after introduction of pneumococcal conjugate vaccine in the Basque country of Spain. Pediatr. Infect. Dis. J.26(8), 667–671 (2007).
   PubMed Web of Science ®Google Scholar
• Barricarte A, Castilla J, Gil-Setas A et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case–control study. Clin. Infect. Dis.44(11), 1436–1441 (2007).
   PubMed Web of Science ®Google Scholar
• Salleras L, Dominguez A, Ciruela P et al. Changes in serotypes causing invasive pneumococcal disease (2005–2007 vs. 1997–1999) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine. Clin. Microbiol. Infect.15(11), 997–1001 (2009).
   PubMed Web of Science ®Google Scholar
• Aguiar SI, Serrano I, Pinto FR, Melo-Cristino J, Ramirez M. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin. Microbiol. Infect.14(9), 835–843 (2008).
   PubMed Web of Science ®Google Scholar
• Dias R, Canica M. Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine. FEMS Immunol. Med. Microbiol.51(1), 35–42 (2007).
   PubMed Web of Science ®Google Scholar
• Rückinger S, van der Linden M, Reinert RR, von Kries R, Burckhardt F, Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine27(31), 4136–4141 (2009).
   PubMed Web of Science ®Google Scholar
• Vestrheim DF, Hoiby EA, Bergsaker MR, Ronning K, Aaberge IS, Caugant DA. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine28(10), 2214–2221 (2010).
   PubMed Web of Science ®Google Scholar
• Rodenburg GD, de Greeff SC, Jansen AG et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, The Netherlands. Emerg. Infect. Dis.16(5), 816–823 (2010).
   PubMed Web of Science ®Google Scholar
• de Greef SC, de Melker HE, Schouls LM, Rodenburg GD, Sanders EAM, van der Ende A. Impact of seven-valent pneumococcal conjugate vaccine on the incidence and serotype distribution of invasive pneumococcal disease in The Netherlands. Presented at: The 7th International Symposium on Pneumococci and Pneumococcal Diseases. Tel Aviv, Israel, 14–18 March 2010.
   Google Scholar
• Harboe ZB, Valentiner-Branth P, Benfield TL et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine2642–2647 (2010).
   PubMed Web of Science ®Google Scholar
• Rendi-Wagner P, Paulke-Korinek M, Kundi M et al. National paediatric immunization program of high risk groups: no effect on the incidence of invasive pneumococcal diseases. Vaccine27(30), 3963–3968 (2009).
   PubMed Web of Science ®Google Scholar
• Hicks LA, Harrison LH, Flannery B et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J. Infect. Dis.196(9), 1346–1354 (2007).
   PubMed Web of Science ®Google Scholar
• Hanna JN, Humphreys JL, Murphy DM. Invasive pneumococcal disease in Indigenous people in north Queensland: an update, 2005–2007. Med. J. Aust.189(1), 43–46 (2008).
   PubMed Web of Science ®Google Scholar
• Johnson HL, Deloria-Knoll M, Levine OS et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med.7(10), pii: e1000348 (2010).
   Google Scholar
• Choi EH, Kim SH, Eun BW et al.Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg. Infect. Dis.14(2), 275–281 (2008).
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J. Infect. Dis.199(6), 776–785 (2009).
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Rose CE Jr, Fry AM et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J. Infect. Dis.192(3), 377–386 (2005).
   PubMed Web of Science ®Google Scholar
• Principi N, Marchisio P, Schito GC, Mannelli S. Risk factors for carriage of respiratory pathogens in the nasopharynx of healthy children. Ascanius Project Collaborative Group. Pediatr. Infect. Dis. J.18(6), 517–523 (1999).
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews N et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years. Clin. Infect. Dis.49(9), 1318–1325 (2009).
   PubMed Web of Science ®Google Scholar
• Moore MR, Whitney CG. Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect? Clin. Infect. Dis.46(2), 183–185 (2008).
   PubMed Web of Science ®Google Scholar
• Amrine-Madsen H, Van EJ, Mera RM et al. Temporal and spatial distribution of clonal complexes of Streptococcus pneumoniae isolates resistant to multiple classes of antibiotics in Belgium, 1997 to 2004. Antimicrob. Agents Chemother.52(9), 3216–3220 (2008).
   PubMed Web of Science ®Google Scholar
• Moore MR. Rethinking replacement and resistance. J. Infect. Dis.199(6), 771–773 (2009).
   PubMed Web of Science ®Google Scholar
• van Gils EJ, Veenhoven RH, Hak E et al. Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA304(10), 1099–1106 (2010).
   PubMed Web of Science ®Google Scholar
• Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin. Infect. Dis.35(5), 547–555 (2002).
   PubMed Web of Science ®Google Scholar
• Henriques NB, Kalin M, Ortqvist A et al. Dynamics of penicillin-susceptible clones in invasive pneumococcal disease. J. Infect. Dis.184(7), 861–869 (2001).
   PubMed Web of Science ®Google Scholar
• Leimkugel J, Adams FA, Gagneux S et al. An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics. J. Infect. Dis.192(2), 192–199 (2005).
   PubMed Web of Science ®Google Scholar
• Aguiar SI, Pinto FR, Nunes S et al. Denmark14–230 clone as an increasing cause of pneumococcal infection in Portugal within a background of diverse serotype 19A lineages. J. Clin. Microbiol.48(1), 101–108 (2010).
   PubMed Web of Science ®Google Scholar
• Dortet L, Ploy MC, Poyart C, Raymond J. Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology. Diagn. Microbiol. Infect. Dis.65(1), 49–57 (2009).
   PubMed Web of Science ®Google Scholar
• Munoz-Almagro C, Esteva C, de Sevilla MF, Selva L, Gene A, Pallares R. Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona. J. Infect.59(2), 75–82 (2009).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Waight P, Andrews NJ et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996–2006. J. Infect.60(3), 200–208 (2009).
   PubMed Web of Science ®Google Scholar
• Hanage WP, Kaijalainen TH, Syrjanen RK et al. Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in Finland. Infect. Immun.73(1), 431–435 (2005).
   PubMed Web of Science ®Google Scholar
• Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J. Infect. Dis.187(9), 1424–1432 (2003).
   PubMed Web of Science ®Google Scholar
• Brueggemann AB. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog.3(11), e168 (2007).
   PubMed Web of Science ®Google Scholar
• Jansen AG, Rodenburg GD, van der EA et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin. Infect. Dis.49(2), e23–e29 (2009).
   PubMed Web of Science ®Google Scholar
• Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, Spratt BG. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J. Infect. Dis.190(7), 1203–1211 (2004).
   PubMed Web of Science ®Google Scholar
• Sjostrom K, Spindler C, Ortqvist A et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin. Infect. Dis.42(4), 451–459 (2006).
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Thomsen RW, Riis A et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med.6(5), e1000081 (2009).
   PubMed Web of Science ®Google Scholar
• Martens P, Worm SW, Lundgren B, Konradsen HB, Benfield T. Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect. Dis.4, 21 (2004).
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Trzcinski K, Lu YJ et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS. Pathog.5(6), e1000476 (2009).
   PubMed Web of Science ®Google Scholar
• Ruckinger S, von KR, Siedler A, van der Linden M. Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatr. Infect. Dis. J.28(2), 118–122 (2009).
   PubMed Web of Science ®Google Scholar
• Alanee SR, McGee L, Jackson D et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin. Infect. Dis.45(1), 46–51 (2007).
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, Hak E, van der Werf TS, Postma MJ. Results of a cohort model analysis of the cost–effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in The Netherlands. Clin. Ther.32(8), 1517–1532 (2010).
   PubMed Web of Science ®Google Scholar
• Tan TQ. Serious and invasive pediatric pneumococcal disease: epidemiology and vaccine impact in the USA. Expert Rev. Anti Infect. Ther.8(2), 117–125 (2010).
   PubMed Web of Science ®Google Scholar
• Wals PD, Carbon M, Sevin E, Deceuninck G, Ouakki M. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr. Infect. Dis. J.28(9), e271–e275 (2009).
   Google Scholar
• Fenoll A, Gimenez MJ, Vicioso MD, Granizo JJ, Robledo O, Aguilar L. Susceptibility of pneumococci causing meningitis in Spain and prevalence among such isolates of serotypes contained in the 7-valent pneumococcal conjugate vaccine. J. Antimicrob. Chemother.64(6), 1338–1340 (2009).
   PubMed Web of Science ®Google Scholar
• Vestrheim DF, Lovoll O, Aaberge IS et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine26(26), 3277–3281 (2008).
   PubMed Web of Science ®Google Scholar
• Jansen AG, Rodenburg GD, Greef SC et al. Invasive pneumococcal disease in The Netherlands: syndromes, outcome and potential vaccine benefits. Vaccine27, 2394–2401 (2009).
   PubMed Web of Science ®Google Scholar